MAPT and Alzheimer disease: Recent late phase clinical trials targeting the major pathological hallmarks of AD, mainly extracellular Aβ plaques or intra-neuronal tau aggregates, have been unsuccessful so far and have failed to prevent cognitive decline and brain atrophy in AD patients [7, 19, 37, 39].